



Semi-annual Report June 2021

ESGTI AG

ESGTI

Table of Contents

Chairman's note.....	3
Investment context, Portfolio, Impact and ESG.....	4
Consolidated condensed interim financial statements.....	6
Investors information.....	19

Publication date

This report was released for publication on 23 Sep 2021.

Amounts in this report are stated in Swiss Francs ("CHF") unless otherwise stated.

Disclaimer

This document is for information only and is not an offer to sell or an invitation to invest. In particular, it does not constitute an offer or solicitation in any jurisdiction where it is unlawful or where the person making the offer or solicitation is not qualified to do so or the recipient may not lawfully receive any such offer or solicitation. It is the responsibility of any person in possession of this document to inform themselves of, and to observe all applicable laws and regulations of relevant jurisdictions.

All statements contained herein that are not historical facts including, but not limited to, statements regarding anticipated activity are forward looking in nature and involve a number of risks and uncertainties. Actual results may differ materially. Readers are cautioned, not to place undue reliance on any such forward-looking statements, which statements, as such, speak only as of the date made.

Chairman's note

The first half of 2021 was a successful period for ESGTI AG on many levels. Our equity base increased 21 %, we saw several significant development steps from our portfolio companies and our team of subject matter experts continued to expand; guiding and validating our investment choices.

As the world continues to experience the effects of the Covid-19 pandemic, it's resilience and reach remain a humbling experience for everyone. Such events have accelerated shifts in behaviour but have also caused us to pause, reflect and slow down in other ways. More than ever, there is a profound call to respect life on earth and each other. A growing awareness of how health, nutrition and the security of the planet are interlinked convince us that our focus areas of food, health and energy continue to be aligned with today's needs and echo the consumer voice.




In May, our portfolio company ESG Eko Agro Group signed a pilot protocol agreement with the Tuscany Region in Italy for the launch of their Carbon Free digital certification of its "Made in Tuscany" food products. As entrepreneurial actors in the AgTech domain, we are proud to support this major step in their journey to reset agricultural methods; tackling systemic problems of food security for the future.

In parallel, our Board approved financing of two major final development stages in both our Energy and Life Sciences pillars; making the goal of bringing technology to fruition a reality and allowing the completion of a key product study for Syndermix's most advanced medical device.

As we have said before, we believe that what sets ESGTI apart is the passion, commitment and involvement of our team. We expanded our Board in June 2021 and now welcome our subsequent new Board member Kim Marty whose election will strengthen the diversity and experience of our leadership team. Likewise we continue to independently evaluate our ESG profile, turning to the eligibility of our investments within the EU Taxonomy to help investors make more informed decisions.

At the time of publication we will be on the cusp of moving our listing to the BX Swiss. Our planned partnership with BX Swiss is a strategic move to target fast growth and benefit from their specialist focus on SMEs and impact driven companies. As a Swiss company we are delighted to bring back our trading core to a country which reflects our heritage and standards and look forward to sharing this move with you!

Hünenberg, September 2021, Andreas R. Bihrer, Chairman



ESGTI: Today's investment context

The European Green Deal has the ambition of making Europe the first climate neutral continent by 2050. At the heart of this is the European Farm to Fork strategy which is designed to address the challenges of today's food systems and the Commission's agenda to achieve UN Sustainable Development Goal (SDG) targets.


At ESGTI the contents of this deal are significant as they recognise the inextricable link between healthy people, healthy society and a healthy planet. The decisions we make towards where and how we invest continue to be focused on the same issues - nutrition, health and climate - to support long term sustainability.

Recent events have inflamed problems of food scarcity, social issues and an increasingly volatile climate. As the global conversation spreads, bodies such as NGOs, institutions and experts become less visible in the conversation. Community mobilisation sees the layman stepping up in his responsibility and we believe impact investors are an essential part of a holistic solution too. This momentum of "conscious capital" allows us to follow our portfolio strategy whilst providing investors with a set of reliable growth segments.




Our Portfolio

Our focus lies in the potential of technology to deliver high-impact solutions to the global challenges that are shaping our future. By concentrating our portfolio into three core pillars we streamline our investment, knowledge and synergies in the following manner:



Impact and ESG Ratings

Following an in-depth assessment of the Environmental and Social ratings of our portfolio we were pleased to share the highlights with our readers from H1 2021:



Overall Social and Environmental Rating

Evaluating our ESG scores within the portfolio allows us to look in-depth at our activities. Within the environmental field we gained a high score via the promotion of sustainable agriculture, production of low environmental impact electric instruments and the retail of wind electric power. Production of health equipment, cruelty-free cosmetics and cooperation with local farmers support ESGTI's positive Social grade. We are proud to score above average for our sector, but we see this rating as a starting point for future improvements. Indeed, the ability to demonstrate sustainability impact improvements requires a timeframe in which to work: this is now a focus for the rest of 2021 alongside extending our Impak analysis throughout the portfolio.

UN SDGs and EU Taxonomy

It is of ongoing importance to us to understand how our portfolio companies can align their activities with the UN's SDGs and the EU Taxonomy, particularly as most of the impact is driven at this level. With an increasing focus on the latter, we are working with independent rating firm Impak to provide investors with more granular information. For example, can the economic activities of our companies can be considered environmentally sustainable and how we allow investors to be protected against greenwashing.

ESGTI Sector and Regulatory ratings



No controversial sectors

Inrate has certified that nor ESGTI or its investments are involved in any controversial or critical sectors. Whilst we knew this, it is relevant for us to be eligible for the Swiss Performance ESG Index.



EU Taxonomy

We are partnering with Impak to assess EU Taxonomy eligibility of every portfolio company. So far our AgTech pillar has been evaluated as potentially eligible and we will continue with our Clean Tech pillar in 2021.



CSR Focus

Our CSR grades are currently below average as ESGTI is a new company and improvements therefore require time to track. We are transparent about this and highlight this as a focus area for 2021-2022.

Statement of comprehensive income (unaudited)

(all amounts in CHF unless otherwise stated)

	Note	01.01.2021-30.06.2021	01.01.2020-30.06.2020
Net change in value of investments through profit or loss	3	934,181	6,466,166
Unrealised gain on loan receivable at fair value through profit or loss	6	2,878,301	2,181,508
Result from investments		3,812,482	8,647,674
Investment advisory fees		-470,692	-526,734
Directors Fees		-53,560	-84,000
Administration fees		-68,900	-64,500
Legal fees		-171,557	-115,165
Audit fees		-120,281	-83,715
Equity and debt issuance related costs		-19,036	-730,903
Structuring and organisational costs		-	-72,592
Financial income		53,021	7,455
Other administrative and operational expenses		-116,673	-27,735
Operating result before financial result and taxes		2,844,805	6,949,784
FX gain / loss		16,046	-571,692
Financial expenses		-2,441,439	-1,631,638
Proportionate result of Associate	4	84,021	145,255
Earnings before tax		503,432	4,891,709
Income taxes	10	-	-30,000
Deferred taxes		-	-729,256
Net result for the period		503,432	4,132,453
Total comprehensive income attributable to:			
Shareholders		503,432	4,132,453
Earnings per share attributable to Shareholders			
Weighted average number of shares outstanding during the period		24,822,942	11,869,207
Basic earnings per share (CHF)		0.02	0.35
Diluted earnings per share attributable to Shareholders	2.9		
Weighted average number of outstanding and potential shares outstanding during the period		38,701,609	25,747,874
Diluted earnings per share (CHF)		0.05	0.16

The accompanying notes form an integral part of these financial statements.

Balance sheet (unaudited)

all amounts in CHF unless otherwise stated

	Notes	30.06.2021	30.12.2020
Assets			
Current assets:			
Cash and cash equivalents		59,394	49,823
Receivables and other assets	7	2,494,174	3,259,051
Total current assets		2,553,568	3,308,874
Non-current assets:			
Current accounts with investments	5	31,658,064	13,770,231
Investment in Associate	4	408,204	324,183
Investments at fair value through profit and loss	3	66,734,533	65,800,353
Loan receivable	6	89,822,194	86,943,893
Total non-current assets		188,622,995	166,838,659
Total assets		191,176,563	170,147,533
Liabilities			
Current liabilities:			
Accrued expenses and other payables		3,117,410	2,456,024
Short-term financial liabilities	8	5,280,605	2,496,562
Provisions direct taxes		59,609	60,000
Total current liabilities		8,457,624	5,012,586
Non-current liabilities:			
Long term financial liabilities	8	83,272,000	83,272,000
Total non-current liabilities		83,272,000	83,272,000
Equity			
Shareholders' equity:	9		
Share capital		40,537,176	33,875,757
Capital reserves		50,289,300	39,870,159
Retained earnings		8,117,030	892,109
Result of the period		503,432	7,224,922
Total shareholders' equity		99,446,939	81,862,947
Total liabilities and shareholders' equity		191,176,563	170,147,533
Number of outstanding shares		25,985,369	21,715,229
Net asset value (NAV) per share (CHF)	2.6	3.83	3.77

The accompanying notes form an integral part of these financial statements.

Statement of cash flows (unaudited)

(all amounts in CHF unless otherwise stated)

	Note	01.01.2021-30.06.2021	01.01.2020-30.06.2020
Expenses paid (administrative and other operating expenses)		-152,803	-137,089
Taxes paid		-391	-6,453
Loans granted		-433,311	-
Net cash flows from operating activities		-586,504	-143,542
Interest paid		-2,387,511	-
Loans repaid / financing provided		-	-789,156
Loans received		2,985,003	943,474
Net cash flows from financing activities		597,492	154,318
Currency translation differences on cash and cash equivalents		-1,417	-2,501
Net change in cash and cash equivalents		9,571	8,275
Cash and cash equivalents at beginning of period		49,823	15,622
Cash and cash equivalents at end of period		59,394	23,897

The accompanying notes form an integral part of these financial statements.

Statement of changes in equity (unaudited)

(all amounts in CHF unless otherwise stated)

	Note	Share capital	Capital reserve	Retained earnings	Total shareholders' equity
Balance as per 1 January 2020		8,385,000	-	940,523	9,325,523
Comprehensive result				4,132,453	4,132,453
Capital increase		21,453,803	33,555,949		55,009,752
Balance as per 30 June 2020		29,838,803	33,555,949	5,072,976	68,467,728
Balance as per 1 January 2021		33,875,757	39,870,159	8,117,031	81,862,946
Comprehensive result				503,432	503,432
Capital increase		6,661,419	10,419,142		17,080,561
Balance as per 30 June 2021		40,537,176	50,289,300	8,620,463	99,446,939

The accompanying notes form an integral part of these financial statements.

Notes to the consolidated condensed interim financial statements (unaudited)

1. Organisation and business activity

ESGTI Ltd. ("ESGTI" or the "Company") is domiciled at Bösch 37, Hünenberg, Switzerland.

ESGTI's investment objective is to provide shareholders with long term capital growth by investing in or financing, directly or through investment companies, early-stage companies or projects with transformative impact objectives. Investments may include investments in private equity and private equity related instruments and opportunistically in certain categories of credit products. Net profits generated upon realizations will typically be re-invested.

2. Summary of accounting policies

The significant accounting policies adopted in the preparation of these consolidated condensed interim financial statements ("Interim Financial Statements", "IFS") are set out below. The Interim Financial Statements comprise ESGTI, and the non-consolidated investments in (i) ESG LifeSciences Ltd., Hünenberg, Switzerland ("ESG-LS"), (ii) ESG Eko Agro Group s.r.l., Bologna, Italy ("ESG EA"), (iii) Sky Energy Ltd, Hünenberg, Switzerland ("Sky"), (iv) AltEnergis plc, London, United Kingdom ("AltEnergis"). The non-consolidated investee companies are referred to as Investment or Investments respectively if not addressed by name.

ESGTI further holds a minority equity stake in ESG Engineering & Consulting Ltd., Zürich, Switzerland ("ESG E&C"). ESG E&C acts as the investment advisor of ESGTI and is accounted for at equity, see note 2.7. ESG E&C is referred to as Associate or Investment Adviser if not addressed by name.

2.1. Basis of preparation

The consolidated condensed interim financial statements as per 30 June 2021 are prepared in accordance with IAS 34 Interim Financial Reporting and comply with Swiss Law. These Interim Financial Statements do not include all the information and disclosures required in annual financial statements. Accordingly, this report is to be read in conjunction with the annual report for the year ended 31 December 2020.

Unless indicated otherwise, the values are in Swiss Francs ("CHF"); the reporting and functional currency of the Company.

2.2. New or amended standards and interpretations applied for the first time during the year under review

ESGTI complies with the standards and amendments to published standards that are mandatory for the financial year beginning on or after 1 January 2020:

- Amendments to IFRS 3, "Business Combinations", definition of a business (1 January 2020);
- Amendments to IAS 1 and IAS 8, "Presentation of Financial Statements" and "Accounting Policies, Changes in Accounting Estimates and Errors", definition of material (1 January 2020);
- Amendments to IFRS 7 and IFRS 9, "Financial Instruments: Disclosures" and "Financial Instruments", pre-replacement issues in the context of the IBOR reform (1 January 2020); and
- Amendments to References to the Conceptual Framework in IFRS Standards (1 January 2020).

Standards and amendments to published standards effective after 1 January 2021 that have not been early adopted:

- A number of new standards, amendments to standards and interpretations are effective for annual periods beginning after 1. January 2021. Those have not been applied in preparing these Financial Statements. None of these could have a significant effect on the Group Financial Statements.

The Company has assessed the potential impact of any new standards, amendments and interpretations. Based on the analysis performed, the Group concludes that the new standards had no material impact on the Group's accounting policies, its overall results and financial positions.

2.3. Significant accounting judgements, estimates and assumptions

The preparation of the Interim Financial Statements requires the Board of Directors to make estimates which affect reported earnings, expenditure, assets, liabilities and investment commitments as at the balance sheet date. The same accounting policies and methods of computation are followed in these Interim Financial Statements as compared with the most recent annual statements. Details on the fair value measurements of the investments are provided below.

A high degree of uncertainty is attached specifically to estimating the fair value of the Investments as those Investments are in private companies and funds which are not actively traded. The fair value of investments that are not traded in an active market are determined by using appropriate methods in accordance with the valuation policies. The use of valuation techniques requires estimates made by the Board of Directors. Changes in assumptions could affect the disclosed fair value of these investments. Valuation policies are disclosed in the latest annual financial statements.

2.4. Foreign currencies

The functional currency for the Company is CHF. Transactions in foreign currencies are accounted for at the exchange rate on the date of the transaction. Monetary assets and liabilities in foreign currencies are converted into Swiss francs at the exchange rates prevailing on the balance sheet date. The resulting foreign currency gains or losses are accounted for through profit and loss.

The following exchange rates were used in the preparation of these Interim Financial Statements:

<u>Exchange rates to CHF</u>	30.06.2021	30.12.2020
EUR	1.0968	1.0809
USD	0.9247	0.8848
GBP	1.2785	1.2088

2.5. Earnings per share and net asset value

Earnings per share are calculated by dividing the net result for the year that is due to shareholders by the time-weighted average number of shares in circulation during the same period.

Diluted earnings per share are calculated by dividing the net result for the year adjusted for income related to potential outstanding shares that is due to shareholders by the sum of the time-weighted average number of shares in circulation during the same period, adjusted for costs and for the potential issue of new shares in

connection with outstanding convertible bonds, share options and similar instruments if those costs are material.

	Note	30.06.2021	30.12.2020
Diluted earnings per share			
Net result for the period		503,432	4,132,453
Adjusted for interest savings on convertible bonds	8	1,367,528	-
Adjusted net result for the period		1,870,960	4,132,453
Weighted average number of ordinary shares outstanding		24,822,942	11,869,207
Adjustments for potential shares outstanding for convertible bonds	8	13,878,667	13,878,667
Total of ordinary and potential shares outstanding		38,701,609	25,747,874
Diluted earnings per share		0.05	0.16

The net asset value per share ("NAV") is calculated from the shareholders' equity reported as at the balance sheet date, divided by the number of shares outstanding on that date.

2.6. Segment reporting

ESGTI's business purpose is the long-term capital growth for shareholder under the consideration of Impact or ESG principles. The Board of Directors values these Investments based on the fair values calculated for each Investment as presented in these financial statements. The portfolio is managed as a whole on a fair value basis and therefore is only one operating segment. Note 3 shows geographical information about the underlying investments.

3. Investments

Name, Domicile	Note	first Purchase	Cost (kCHF)	Fair Value (kCHF) (31.12.20)	Fair Value (kCHF) (30.06.21)	gain/loss(-) (YTD)	latest valuation	Valuation method
ESG LifeSciences Ltd, CH	3.1	2020	29,300	30,048	30,982	1,682	2020	NAV
Investments held								
SynDermix Ltd, CH		2018		38,699	57,915		2020	latest transaction price
Enielle Ltd, CH		2019		2,628	2,628		2020	latest transaction price
Rheon Medical SA, CH		2020		617	617		2020	latest capital increase
ESG Eko Agro Group s.r.l., IT	3.2	2020	67	67	67	-	2020	latest capital increase
AltEnergis plc, UK	3.3	2020	23,701	35,285	35,285	11,584	2020	latest transaction price
SkyEnergy Ltd, CH	3.4	2020	400	400	400	-	2020	latest transaction price
Total			53,468	65,800	66,735	13,266		

For the current period, the Company presents a net change in value of investments through profit or loss amounting to CHF 934,181; a change predominantly driven by a share swap of SynDermix shares held by minority shareholders to ESGTI shares. As ESGTI shares bring them with the benefit of trade-able stocks (as opposed to SynDermix shares which are not), this share swap occurred at a value below the ESGTI

determined fair value; hence the resulting uplift. The valuation at CHF 4.50 per share of SynDermix – the latest transaction price in December 2020 – is still considered to be the most recent fair value.

For the comparative period, the Company presents a net change in value of investments through profit or loss amounting to CHF 6,466,166. This change arose as the Company revalued their investments held after identifying itself as an investment entity under IFRS 10 and preparing the first semi-annual financial reporting under IFRS. Comparison between these two periods should therefore be made with caution as H1 2020 is not representative of organic company performance.

3.1. ESG LifeSciences Ltd., Hünenberg, Switzerland

ESG LifeSciences Ltd. is a Swiss investment company with registered office in Hünenberg, Switzerland focusing on investments in the life sciences and advised by Dragon Finance Ltd, Zurich, Switzerland.

100% of the shares of ESG-LS were purchased at 1 January 2020. ESG-LS is invested in three companies:

- SynDermix Ltd., Stans, Switzerland, a Swiss developer of innovative health technologies funded by private investors. The Company focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs. As of 30 June 2021, ESG-LS held 64.6% of SynDermix AG (31 December 2020: 42.4%). ESG-LS values the SynDermix shares at CHF 4.50 per share which was the latest transaction price in December 2020. The latest transaction price is considered to be the most recent fair value.
- Énielle Ltd., Zürich, Switzerland, a Swiss developer of nature-based cosmeceuticals, 80% owned by ESG-LS as per 30 June 2021 (80% as per 31 December 2020). Énielle Ltd. plans to enter the market with its product in the second half of 2021. The latest transaction price is considered the most recent fair value.
- Rhéon Medical SA, Prévèrènges, Switzerland, a privately held Swiss medical device company, a spin-off from the Swiss Federal Institute of Technology Lausanne. Rhéon Medical specializes in the field of glaucoma surgery and, in specific, in glaucoma drainage devices. Its mission is to provide optimal solutions to the surgical therapy of glaucoma. As per 30 June 2021, ESG-LS held 3.19% of Rhéon Medical SA (31 December 2020: 3.19%), valued at the last known transaction price as per November 2020 regarding the next two financing rounds of Rhéon Medical SA amounting to a total of CHF 5 million which the Board of Directors deemed to be an appropriate fair value of the shares held.

3.2. ESG Eko Agro Group s.r.l., Bologna, Italy

ESG Eko Agro Group s.r.l. is an Italian investment company focusing on agricultural projects. As at 30 June 2020, the company was 66.6% owned by ESGTI (31 December 2020: 66.6% owned by ESGTI).

ESGTI values ESG EA at the price of the latest capital increase in December 2020 which is considered to be the most recent fair value.

3.3. AltEnergis plc, London, UK

AltEnergis plc is a UK-based, privately funded technology development and commercialisation company. The company focuses on developing innovative technologies within Deep Technology, specifically in CleanTech and MedTech.

ESGTI holds 100% of AltEnergis as at 30 June 2021 (100% as at 31 December 2020). The latest transaction prices in June 2020 are considered to be the most recent fair value.

3.4. Sky Energy Ltd, Hünenberg, Switzerland

Sky Energy Ltd is a Swiss-based energy company with the purpose to acquire and operate renewable energy parks and to supply the generated wind- and solar energy to commercial and residential customers. As of 30 June 2021, ESGTI holds 100% of Sky (31 December 2020: 100% of Sky).

ESGTI purchased Sky at the end of November 2020 for CHF 400,000 which is considered the fair value of Sky at purchase date, as per 31 December 2020, and as per 30 June 2021.

4. Investment in Associate

ESG Engineering & Consulting Ltd. is a Swiss company with registered office in Zurich, Switzerland. ESG E&C is the Investment Advisor for ESGTI, ESGTI holds 40% of ESG E&C as per 30 June 2021 and as per 31 December 2020.

	30.06.2021	30.12.2020
Associated company at equity:		
ESG Engineering & Consulting Ltd., Zurich, Switzerland, voting/capital rights: 40%		
Purchase price	200,000	200,000
Accumulated proportionate result until beginning of the current period	124,183	16,183
Proportionate result of the current period (comparative: full financial year)	84,021	108,000
Total associated company	408,204	324,183

5. Current accounts with Investments and Associate

ESGTI has current accounts with its Investments and its Associate. Details and movements of these accounts are outlined below.

All current accounts are unsecured. All current accounts with Investments are subject to interest of 7.1% as per 30 June 2021 except the current account with ESG LifeSciences which is subject to 0.25% interest (7.1% as per 31 December 2020). The current accounts are repayable on demand.

	2021	2020
Current accounts with Investments		
ESG LifeSciences Ltd		
As per 1.1.	13,243,210	-
Increase / (-)decrease	17,689,517	13,243,210
As per 30.06. / 31.12.	30,932,727	13,243,210
ESG Eko Agro Group s.r.l		
As per 1.1.	281,619	-
Increase / (-)decrease	93,954	281,619
As per 30.06. / 31.12.	375,573	281,619
AltEnergis plc		
As per 1.1.	245,052	-
Increase / (-)decrease	103,622	245,052
As per 30.06. / 31.12.	348,674	245,052
Sky Energy Ltd		
As per 1.1.	350	-
Increase / (-)decrease	741	350
As per 30.06. / 31.12.	1,091	350
Total current accounts with Investments	31,658,064	13,770,231

6. Loan receivable

	30.06.2021	30.12.2020
Loan receivable		
Loan receivable at cost	81,632,386	81,632,386
Unrealised gain on loan receivable	8,189,807	5,311,506
Total loan receivable	89,822,194	86,943,892

The loan receivable matures as per 31 October 2030 and is held at fair value through profit or loss. The loan is subject to 6.75% interest, the first interest payment is due as per 3 January 2025 with subsequent annual interest payments.

7. Receivables and other assets

	30.06.2021	30.12.2020
Receivables and other assets		
Receivables from Shareholders	2,214,384	3,046,325
Other receivables	279,790	212,726
Total receivables and other assets	2,494,174	3,259,051

8. Financial liabilities

	30.06.2021	30.12.2020
Financial liabilities		
Short-term loan from shareholder	-121,262	-121,262
Short-term loan from others	-4,359,133	-1,561,972
Interest payable from bonds issued	-800,210	-813,328
Financial liabilities payable within 12 months	-5,280,605	-2,496,562
Long-term loan from bonds issued	-83,272,000	-83,272,000
Other long-term liabilities	-	-
Financial liabilities payable after 12 months	-83,272,000	-83,272,000

All financial liabilities are measured at amortised cost.

Short-term loan from shareholder and short-term loan from others are current accounts for financing purposes with shareholders and third parties.

The long-term loan from bonds issued is a tradeable bond, identified with ISIN XS2158598354. The semi-annually payable interest is 5.75%, payment dates are end of April / end of October each year until maturity.

The bonds issued have a conversion right. Details are outlined in the latest annual financial statements.

9. Shareholders' equity

9.1. Share capital and capital reserves

The Company's share capital amounts to CHF 40.5 million as per 30 June 2021, divided into 25,985,369 registered shares at a par value of CHF 1.56 each. All shares are authorised, issued and fully paid-up (31 December 2020: CHF 33.9 million, 21,715,229 registered shares).

Capital reserves of the Company amount to CHF 50.2 million as at 30 June 2021 (31 December 2020: CHF 39.8 million). Pending approval from Swiss tax authorities, capital reserves are withholding tax exempt when distributed to the shareholders.

9.2. Significant shareholders

The following major shareholders were known by the Company at balance sheet date:

	30.06.2021	30.12.2020
More than 20%	Dragon Finance AG, Zurich, Switzerland	Dragon Finance AG, Zurich, Switzerland
Between 10% and 20%	World Markets AG, Hünenberg, Switzerland	World Markets AG, Hünenberg, Switzerland
Between 5% and 10%	-	WP Multi Strategy Fund, George Town, Cayman Islands
Below 5% (free float)	50.93%	40.55%

10. Taxes

Income taxes for the reporting period are zero as it is considered unlikely that the Company will generate income subject to income taxes. For the comparative period, a taxable gain was estimated.

11. Related party transactions

	01.01.2021-30.06.2020	01.01.2020-30.06.2020
Related party transactions		
Remuneration of the Board of Directors		
Chairman	30,000	30,000
Members	60,000	45,000
Waiver of board fee	-40,000	-
Investment Advisor ESG Engineering & Consulting Ltd		
Investment and performance fees	365,067	526,734
downpayments on open invoices	-370,570	-
Transactions with Investments		
Financing provided to Investments	807,273	1,032,933
Sale of Rhéon Medical shares to ESG-LS	-	250,000
Sale of SynDermix shares to ESG-LS	17,080,560	3,287,173
Purchase of AltEnergis shares from ESG-LS	-	3,328,969
Share swap SynDermix shares for ESGTI shares via ESG-LS	-	2,250,000
Transactions with Shareholders		
Financing received from shareholders	297,161	310,000

Related parties are individuals and companies where the individual or company has the ability, directly or indirectly, to control the other party or to exercise significant influence over the other party in making financial or operational decisions. All related party transactions have been carried out within the normal course of business.

Remuneration of the Board of Directors comprise the agreed fees to the members of the Board of Directors without social security contributions. A member of the Board of Directors waived a payable board fee in the current reporting period.

In the reporting period, ESGTI purchased shares of SynDermix Ltd. and settled the purchase price through the issuance of own shares. The purchased shares were transferred to ESG LifeSciences Ltd. at its purchase price.

12. Valuation risks and fair values

Given the uncertainties inherent in valuing private companies, the NAV reported by ESGTI may differ temporarily from the actual fair value of individual investments. As a result of valuation differences owing to the unavailability of information, the estimated values of individual investments may diverge significantly from values that would have been calculated had an active market for such securities existed. Furthermore, the estimated values of individual investments as at a certain balance sheet date may differ significantly from the values which could potentially be realised by means of an exit, an IPO or another event with a participating third-party (i.e. financing round) at any later point in time. Such differences might have a material effect on the valuation of individual investments in the Interim Financial Statements.

IFRS established a fair value hierarchy to determine any fair value based upon the inputs to determine the fair value. Level 1 inputs are quoted prices in active markets for identical assets or liabilities that can be accessed

at the measurement date. Level 2 inputs are inputs other than quoted prices included within Level 1 that are either directly or indirectly observable. Level 3 inputs are unobservable inputs.

All Investments held by ESGTI at fair value through profit and loss are investments where the fair value is based upon Level 3 inputs. There were no assets or liabilities measured at fair value based on Level 1 and Level 2 inputs in the reporting or the comparison period. There has been no change in valuation techniques used for Level 3 investments. The table below presents Investments measured at fair value at the end of the reporting period by the level in the fair value hierarchy into which the fair value measurement is categorised:

Leveling of financial assets (current period)	Level 1	Level 2	Level 3	Total
AltEnergis plc (Investment)	-	-	35,284,938	35,284,938
ESG Eko Agro Group s.r.l. (Investment)	-	-	67,270	67,270
ESG LifeSciences Ltd (Investment)	-	-	30,982,324	30,982,324
Loan receivable (Loan)	-	-	89,822,194	89,822,194
Sky Energy Ltd (Investment)	-	-	400,000	400,000
Total	-	-	156,556,727	156,556,727

Leveling of financial assets (prior period)	Level 1	Level 2	Level 3	Total
AltEnergis plc (Investment)	-	-	35,284,938	35,284,938
ESG Eko Agro Group s.r.l. (Investment)	-	-	67,270	67,270
ESG LifeSciences Ltd (Investment)	-	-	30,048,144	30,048,144
Loan receivable (Loan)	-	-	86,943,893	86,943,893
Sky Energy Ltd (Investment)	-	-	400,000	400,000
Total	-	-	152,744,245	152,744,245

13. Subsequent events

Since the balance sheet date of 30. June 2021 there have been no material events that could impair the integrity of the information presented in these financial statements.

Investors information

Shares

ISIN CH0298294981

Valor 29829498

WKN A1409X

Ticker 02TP (as of 1 October 2021: ESGTI)

Listing

Berlin Stock Exchange (as of 1 October 2021: BX Swiss)

Publication of net asset value

www.esgti.com

Registered office

ESGTI AG; Bösch 37, CH-6331 Hünenberg, Switzerland

Telephone +41 41 500 99 83

Board of Directors

Andreas R. Bihrer, Attorney at Law, Zurich, Switzerland (Chairman)

Brunella Pavesi, PhD, Rome, Italy

Dimitri Dimitriou, MSc, FRSC, FRSB, FIBMS, Freienbach, Switzerland

Kimberley Marty, BSc, Dübendorf, Switzerland

Wolfgang Werlé, BA, Zumikon, Switzerland

Hermann Wirz, BA, Pully, Switzerland

Investment Advisor

ESG Engineering & Consulting AG. Spyristrasse 11, 8044 Zurich, Switzerland

Administrator

ARIA Fund Services, Office 1004, Park Place Tower, Sheikh Zayed Road, PO Box 413670, Dubai, United Arab Emirates